At close: June 25 at 4:00 PM EDT
After hours: June 25 at 4:41 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 5 |
| Avg. Estimate | -0.23 | -0.28 | -1.07 | -0.93 |
| Low Estimate | -0.25 | -0.39 | -1.34 | -1.11 |
| High Estimate | -0.21 | -0.22 | -0.85 | -0.71 |
| Year Ago EPS | -0.43 | -0.34 | -1.5 | -1.07 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 5 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.42 | -0.38 | -0.31 | -0.24 |
| EPS Actual | -0.43 | -0.34 | -0.26 | -0.26 |
| Difference | -0.01 | 0.04 | 0.05 | -0.02 |
| Surprise % | -2.40% | 10.50% | 16.10% | -8.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.23 | -0.28 | -1.07 | -0.93 |
| 7 Days Ago | -0.23 | -0.28 | -1.07 | -0.93 |
| 30 Days Ago | -0.23 | -0.28 | -1.07 | -0.93 |
| 60 Days Ago | -0.22 | -0.28 | -1.03 | -0.9 |
| 90 Days Ago | -0.29 | -0.3 | -1.24 | -0.86 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ACHV | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 46.50% | -- | -- | 7.80% |
| Next Qtr. | 17.60% | -- | -- | 11.00% |
| Current Year | 28.70% | -- | -- | 5.00% |
| Next Year | 13.10% | -- | -- | 12.20% |
| Next 5 Years (per annum) | 15.00% | -- | -- | 11.47% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Oppenheimer: Outperform to Outperform | 5/13/2024 |
| Initiated | JonesTrading: Buy | 4/17/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 4/1/2024 |
| Maintains | Lake Street: Buy to Buy | 3/5/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 12/12/2023 |
| Maintains | Lake Street: Buy to Buy | 5/31/2023 |
Related Tickers
ACRV Acrivon Therapeutics, Inc.
6.06
-3.19%
EYPT EyePoint Pharmaceuticals, Inc.
8.26
-3.05%
MLTX MoonLake Immunotherapeutics
39.70
+2.56%
ELVN Enliven Therapeutics, Inc.
21.47
-1.69%
FENC Fennec Pharmaceuticals Inc.
6.20
-2.36%
BLPH Bellerophon Therapeutics, Inc.
0.0571
0.00%
AKTX Akari Therapeutics, Plc
2.7700
-25.54%
ADAG Adagene Inc.
2.8300
-3.08%
NWRN.SW Newron Pharmaceuticals S.p.A.
9.56
-12.77%
EQ Equillium, Inc.
0.6838
+0.46%